[Continued on next page]

(54) Title: 1, 2, 3, 5 -TETRAHYDROBENZO'C!AZEPIN-4-ONE DERIVATIVES HAVING MUSCARINIC ANTAGONIST ACTIVITY

(57) Abstract: There is disclosed a compound having the formula or a pharmaceutically acceptable salt thereof, wherein: R_{1a}, R_{1b} and R_{1c} are independently fluorine or hydrogen; R_2 is C_1 to C_{12} alkyl being straight or branched chain, saturated or unsaturated, mono-substituted or unsubstituted, said substituents being selected from piperidine,pyrroliding, morpholine, thiomorpholine and cycloalkyl of 3 to 7 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms having a C_1 to C_6 alkyl substituent; a polycycloalkyl of 2 to 3 rings having 7 to 12 carbons; and phenyl or phenyl substituted with halogen, hydroxy, C_1 to C_6 alkoxy, C_1 to C_6 alkyl, nitro, methylene dioxy or trifluoromethyl; and R_3 is a moiety selected from: (I), (II) or a pyrrolidin-3-yl moiety of the formula (III). The compounds are disclosed for use as muscarinic antagonists with M_3 selectivity.

WO 02/06241 A1

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

1,2,3,5-TETRAHYDROBENZO·C1AZEPIN-4-ONE DERIVATIVES HAVING MUSCARINIC ANTAGONIST ACTIVITY

THERAPEUTIC COMPOUNDS

This invention relates to muscarinic antagonists with M_3 selectivity.

Muscarinic M_3 receptors are located predominantly

5   on smooth muscle and salivary glands, and agents selective for this sub-class of receptors may have therapeutic utility in the treatment of incontinence, disorders of gastro-intestinal motility and as bronchodilators in respiratory disease.

10   EP-A-0486734 discloses 1-substituted-1-hydroxy-1-aryl-3-(4-substituted-1-piperizinyl)-2-propanones having antimuscarinic activity.

According to the present invention, there is provided a compound having the formula:

15

20   or a pharmaceutically acceptable salt thereof, wherein:

R_{1a}, R_{1b} and R_{1c} are independently fluorine or hydrogen;

R_2 is C_1 to C_{12} alkyl, said alkyl being straight or branched chain, saturated or unsaturated, mono-

25   substituted or unsubstituted, said substituents being selected from piperidine, pyrrolidine, morpholine, thiomorpholine and cycloalkyl of 3 to 7 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms (preferably 4 to 9 carbon atoms) having

30   a C_1 to C_6 alkyl substituent; a polycycloalkyl of 2 to 3 rings having 7 to 12 carbons, preferably 7-9 carbon atoms; and phenyl or phenyl singly or multiply substituted (preferably singly or doubly) with halogen, hydroxy, C_1 to C_6 alkoxy, C_1 to C_6 alkyl, nitro,

35   methylene dioxy or trifluoromethyl; and

-2-

R_3 is a moiety selected from:

I   II

or a pyrrolidin-3-yl moiety of the formula

III

where R_6 is hydroxy or hydrogen;
where one of R_4 and R_5 is hydrogen or lower C1-3 alkyl
and the other is selected from:

    (a)   hydrogen,

    (b)   phenyl,

    (c)   phenyl singly or multiply substituted with
halogen, hydroxy, C_1 to C_6 alkoxy, C_1 to C_6 alkyl, nitro,
methylene dioxy or trifluoromethyl; and

    (d) C_1 to C_6 alkyl which may be branched chain or
straight, saturated, unsaturated, or cyclic and may be
optionally substituted with hydroxy, thienyl, pyrrolyl,
pyridyl, furanyl, lower alkoxy or acetoxyalkyl wherein
the alkyl group has 1 to 3 carbons, phenyl, phenyl
singly or multiply substituted (preferably singly or
doubly) with halogen, hydroxy, C_1 to C_6 alkoxy, C_1 to C_6
alkyl, nitro, methylene dioxy or trifluoromethyl.

In an embodiment of the invention, R_2 is not a

phenyl or substituted phenyl, R_3 has the structural
formula II or III, and one of R_4 and R_5 is hydrogen
whilst the other is selected from substituents (a),
(b), (c) or (d).

5   **Radical R1a,b,c**

        In embodiments of the invention, R_{1a}, R_{1b} and R_{1c} are
each fluorine or each hydrogen. In other embodiments,
R_{1a} is hydrogen and either one of R_{1b} and R_{1c} is fluorine
and the other is hydrogen or both R_{1b} and R_{1c} are

10   fluorine.

      Radical R2

        When R_2 is substituted C_1-C_{12} alkyl, the substituent
on the alkyl may additionally be selected from
tetrahydrofuran, thiophen and furan. Further, when R_2

15   is C_1-C_{12} alkyl, it is preferred that the alkyl is
saturated.

        In preferred embodiments of the invention, R_2 may
be cycloalkyl of 3 to 6 carbon atoms, for example
cyclohexyl or cyclobutyl, preferably cyclobutyl. In

20   other preferred embodiments of the invention, R_2 may be
phenyl.

      Radicals R4 and R5

        In addition to the above definition, under
alternative (d) for R_4/R_5, the or each alkyl substituent

25   on the phenyl radical may be a C_1-C_{10} alkyl, preferably
a C_5-C_8 alkyl, and the or each alkoxy substituent on the
phenyl radical may be C_1-C_{10} alkoxy.

        Further, in addition to the above definition under
alternative (d) for R_4/R_5, the methylene dioxy

30   substituent may itself be mono or di- substituted by an
alkyl having 1 to 10 carbons, preferably dialkyl-
substituted where each alkyl has from 1 to 5 carbons.

        It is preferred that R_4 is hydrogen and R_5 is
selected from amongst the groups (a)-(d) above.

35   In one embodiment, one of R_4 and R_5 is hydrogen (or

methyl in the case of R_5) and the other is selected from
hydrogen, C_1 to C_6 alkyl which may be branched chain or
straight, saturated, unsaturated, or cyclic and may be
optionally substituted with hydroxy, thienyl, pyrrolyl,
pyridyl, furanyl, phenyl, phenyl singly or multiply
substituted (preferably singly or doubly) with halogen,
hydroxy, C_1 to C_6 alkoxy, C_1 to C_6 alkyl or nitro. More
preferably, one of R_4 and R_5 is hydrogen and the other
is C_1 to C_6 alkyl, benzyl, substituted benzyl or
cinnamyl; such as benzyl or 4-substituted benzyl; for
example benzyl, 4-chlorobenzyl or 4-methylbenzyl.

In another embodiment, it is preferred that R_4 is
hydrogen and R_5 is C_1 to C_6 alkyl substituted by phenyl
or phenyl which is singly or multiply substituted
(preferably singly or doubly) with halogen, hydroxy, C_1
to C_{10} alkoxy, C_1 to C_{10} alkyl or nitro. More
preferably, R_5 is benzyl, substituted benzyl or
cinnamyl. Most preferably, R_5 is substituted benzyl in
which the substituent(s) on the benzyl are
independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl.
For example, the benzyl may be substituted by one or
two alkyls where the total number of carbon atoms in
the alkyl substituent(s) is from 6 to 10. In another
example, the benzyl may be substituted by an alkyl
radical having from 5-9 carbon atoms and a halo,
preferably chloro. Where the benzyl is mono-
substituted, this is preferably in the 3- or 4-
position. Where the benzyl is di-substituted, this is
preferably in the 3- and 4- positions.

Radical R6

It is preferred that R_6 is hydrogen.

Preferred Embodiments of the Invention

In a first preferred embodiment of the invention,
R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine,
R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is

$$\underset{H_2}{\overset{R_4}{\text{C}}}\quad\text{CH}\quad\overset{H}{\text{N}}$$

where R_4 is hydrogen and R_5 is selected from C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, and R_6 is hydrogen or hydroxy. Preferably R_6 is hydrogen.

In this first embodiment, R_2 is preferably cyclohexyl, cyclobutyl or phenyl, more preferably cyclobutyl, and R_5 is preferably C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, such as methyl, benzyl or 4-substituted benzyl, for example benzyl, 4-chlorobenzyl or 4-methylbenzyl.

Alternatively in this first embodiment (and presently preferred), R_5 is substituted benzyl in which the substituent(s) on the benzyl are independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl. For example, the benzyl may be substituted by one or two alkyls where the total number of carbon atoms in the alkyl substituent(s) is from 6 to 10. In another example, the benzyl may be substituted by an alkyl radical having from 5-9 carbon atoms and a halo, preferably chloro. Where the benzyl is mono-substituted, this is preferably in the 3- or 4- position. Where the benzyl is di-substituted, this is preferably in the 3- and 4- positions.

In a second embodiment (which is presently less preferred than the first embodiment) R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is

-6-

where R_5 is hydrogen or methyl and R_4 is C_1 to C_6 alkyl,
benzyl, substituted benzyl or cinnamyl, and R_6 is
hydroxy or hydrogen, preferably hydrogen. In this
second embodiment, R_2 is preferably cyclohexyl,
cyclobutyl or phenyl, more preferably cyclobutyl, and R_4
is preferably C_1 to C_6 alkyl, benzyl, substituted benzyl
or cinnamyl, such as methyl, benzyl or 4-substituted
benzyl, for example benzyl, 4-chlorobenzyl or 4-
methylbenzyl.

In a third embodiment R_{1a}, R_{1b} and R_{1c} are
independently hydrogen or fluorine, R_2 is cycloalkyl of
3 to 6 carbon atoms or phenyl, R_3 is

where R_4 is hydrogen and R_5 is selected from C_1 to C_6
alkyl, benzyl, substituted benzyl or cinnamyl, and R_6 is
hydroxy or hydrogen.

In this third embodiment, R_2 is preferably
cyclohexyl, cyclobutyl or phenyl, more preferably
cyclobutyl, and R_5 is preferably C_1 to C_6 alkyl, benzyl,
substituted benzyl or cinnamyl, such as methyl, benzyl
or 4-substituted benzyl, for example benzyl, 4-
chlorobenzyl or 4-methylbenzyl.

Alternatively in this third embodiment (and
presently preferred), R_5 is substituted benzyl in which
the substituent(s) on the benzyl are independently

-7-

halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl. For example, the benzyl may be substituted by one or two alkyls where the total number of carbon atoms in the alkyl substituent(s) is from 6 to 10. In another example,
5 the benzyl may be substituted by an alkyl radical having from 5-9 carbon atoms and a halo, preferably chloro. Where the benzyl is mono-substituted, this is preferably in the 3- or 4- position. Where the benzyl is di-substituted, this is preferably in the 3- and 4-
10 positions.

In a fourth embodiment (which is presently less preferred than the third embodiment) R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is a
15 pyrrolidin-3-yl moiety having the following structure:

20

where R_5 is hydrogen or methyl and R_4 is C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, and R_6 is hydroxy. In this fourth embodiment, R_2 is preferably cyclohexyl, cyclobutyl or phenyl, more preferably
25 cyclobutyl, and R_4 is preferably C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, such as methyl, benzyl or 4-substituted benzyl, for example benzyl, 4-chlorobenzyl or 4-methylbenzyl.

In a fifth embodiment R_{1a}, R_{1b} and R_{1c} are
30 independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is a moiety having the following structure:

35

-8-

$$\underset{H_2}{C}\!\!-\!\!\overset{R_4}{\underset{}{CH}}\!\!-\!\!\overset{}{\underset{R_5}{N}}\!\!-\!\!H\ ;$$

where R_4 is hydrogen and R_5 is selected from C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl.

In this fifth embodiment, R_2 is preferably cyclohexyl, cyclobutyl or phenyl, more preferably cyclobutyl, and R_5 is preferably C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, such as methyl, benzyl or 4-substituted benzyl, for example benzyl, 4-chlorobenzyl or 4-methylbenzyl.

Alternatively in this fifth embodiment (and presently preferred), R_5 is substituted benzyl in which the substituent(s) on the benzyl are independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl. For example, the benzyl may be substituted by one or two alkyls where the total number of carbon atoms in the alkyl substituent(s) is from 6 to 10. In another example, the benzyl may be substituted by an alkyl radical having from 5-9 carbon atoms and a halo, preferably chloro. Where the benzyl is mono-substituted, this is preferably in the 3- or 4- position. Where the benzyl is di-substituted, this is preferably in the 3- and 4-positions.

In a sixth embodiment (which is presently less preferred than the fifth embodiment) R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is

$$
\begin{array}{c}
R_4 \\
| \\
CH \quad\quad\quad H \\
\diagdown \quad \diagup \\
C \quad\quad N \\
H_2 \quad\quad \diagdown \\
\quad\quad R_5
\end{array}
$$

where R_5 is hydrogen or methyl and R_4 is C_1 to C_6 alkyl,
benzyl, substituted benzyl or cinnamyl. In this sixth
embodiment, R_2 is preferably cyclohexyl, cyclobutyl or
phenyl, more preferably cyclobutyl, and R_4 is preferably
C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl,
such as methyl, benzyl or 4-substituted benzyl, for
example benzyl, 4-chlorobenzyl or 4-methylbenzyl.

In each of the first to sixth embodiments
described above, it is preferred that R_{1a} is hydrogen
and either one of R_{1b} and R_{1c} is fluorine and the other
is hydrogen or both R_{1b} and R_{1c} are fluorine.

As used herein, unless otherwise specified, lower
alkyl and lower alkoxy refer to groups having 1 to 6
carbons. The invention also relates to the
pharmaceutically acceptable salts of the foregoing
compounds and to pharmaceutical compositions containing
effective amounts of such compounds; the compounds and
compositions may be used for the manufacture of a
medicament for the treatment of bladder disorders.

The compounds of the invention may be used in the
neutral form. Alternatively, the compounds may be used
in the form of pharmaceutically acceptable salts.
Salts of the compounds of the invention include the
acid salts such as the hydrochloride, sulfate,
phosphate, nitrate, methanesulfonate and tartrate
salts. Other pharmaceutically acceptable salts are
also included in the invention, as are the various
possible hydrates of each of the compounds. As will be
understood by those skilled in the art, compounds of

-10-

this invention may be present as _d_ or _l_ optical isomers as well as racemic mixtures thereof. Further, some of the compounds in which R_1 is a substituted cycloalkyl or a polycycloalkyl may be present as diastereoisomers

5   which may be resolved into optical isomers. Resolutions of optical isomers may be accomplished by fractional crystallization of their salts with optically active acids such as, for example, tartaric, camphor-10-sulfonic, O,O-dibenzoyltartaric, O,O-di(p-

10   toluoyl) tartaric, menthyloxyacetic, camphoric, or 2-pyrrolidone-5-carboxylic acids of N-acetyltryptophane from appropriate solvents. They may also be prepared by stereoselective synthesis or by chromatographic techniques using chiral substrates or derivatives.

15   Unless otherwise specified in the claims, it is intended to include all isomers, whether separated or mixtures thereof.

       Preferred isomers have the following stereochemistry:

20

25

30

The protonated form of the respective R_3 side chains is shown.

       The compounds of the invention may be administered in a variety of pharmaceutical preparations well known

35   to those skilled in the pharmaceutical art. For

parenteral administration, the compounds may be prepared in aqueous injection solutions which may contain antioxidants, buffers, bacteriostats, and other additives commonly employed in such solutions.

5   Extemporaneous injection solutions may be prepared from sterile pills, granules or tablets which may contain diluents, dispersing and surface active agents, binders, and lubricants as well as the compound of the invention.

10   In the case of oral administration, fine powders or granules of the compound of the invention may be formulated with diluents and dispersing and surface active agents, and may be prepared in water, a syrup, capsules, cachets, a non-aqueous suspension or an

15   emulsion. In dry forms, optional binders and lubricants may be present. The compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents and other pharmaceutically acceptable additives. Granules or

20   tablets for oral administration may be coated. In general, the compositions of the invention include the compounds of the invention in a pharmaceutically effective amount in a pharmaceutically acceptable carrier.

25   The compounds are useful as antimuscarinic agents selective for the muscarinic M3 receptor; more particularly, they are useful as bronchodilators, as antispasmodics, antisecretory agents, have antiulcer activity and are useful in the treatment of patients

30   suffering from neurogenic bladder disorders. The compounds are administered in pharmaceutically effective amounts. Daily dosages will generally be at a rate of 5 to 100 mg/day, more specifically 10 to 40 mg/day. Because of their duration of action the

35   compounds may be administered less frequently than

-12-

certain prior art antimuscarinic agents, particularly those used in the treatment of neurogenic bladder disorder.

5   The compounds of the invention may be tested to determine their muscarinic activity in accordance with the procedure set forth in EP-A-0486734. The compounds may also be tested for their M_1, M_2 and M_3 receptor activity using the assays set forth after the examples below.

10   According to a process aspect of the present invention, the compounds of the invention process may be synthesised by a process which includes the step of subjecting a compound of the formula (X):

15

X

in which R1a, R1b, R1c and R2 are as defined above and
20   R3 is as defined above suitably protected,
to oxidation conditions sufficient to oxidise the alcohol group at the 4-position of the benzo[c]azepine core to a ketone group.

For example, the R_3 groups may be protected as
25   follows

I

II

30

III

35

in which Y is hydrogen or a hydroxy protecting group
such as acetyl, and X is an amine protecting group such
as a trifluoroacetamide or a nosyl group. In Formula
III the nitrogen group only requires protection where R_5
in the final molecule is hydrogen.

The oxidation step to oxidise the alcohol group at
the 4-position of the benzo[c]azepine core to a ketone
group is preferably a Swern oxidation step (K.
Takahashi, M. Ogata, J. Org. Chem, 1987, 52, 1877).

In this process aspect of the invention, the
compound X may be made by a process in which a compound
of the formula XI

XI

is subjected to a reductive amination with an
aldehyde/ketone corresponding to $\bar{R}_3$, suitably protected.
For example, one of the following protected aldehyde
or ketone may be employed:

Ia

IIa

IIIa

where X and Y are as defined above.

This reductive amination may be accomplished

-14-

following the procedure of Borch et al. (R.F. Borch,
M.D. Bernstein, H.D. Hurst, J. Am. Chem. Soc., 1971,
93, 2897) using the reagent $NaBH_3CN$ at an optimum pH of
about 6.

5   Details of the routes to the compound XI and
reagents Ia, IIa and IIIa are discussed in detail
below.

The following section concerns the synthesis of
compounds in accordance with the invention in which
10   each of R_{1a}, R_{1b} and R_{1c} is hydrogen, and uses as starting
material the commercially available compound phthalide
(isobenzofuran).

15

20

-15-

Synthesis of 2-Azepine Core Unit:

M = MgBr, or Li; DMI = Dess-Martin Iodinane;
RCM = Ring Closing Metathesis.

Ketone 5 is accessed in two ways via the Weinreb amide
2 or via an addition-oxidation protocol. 6 is prepared
by treatment of 5 with the Petasis reagent (Cp₂TiMe₂).
Deprotection, oxidation followed by a two step
reductive amination gives the dialkenyl amine 9.
Nitrogen derivatisation with 2-nitrophenyl sulfonyl
chloride gives 10 which is converted to the
dihydroazepine 11 using tricyclohexylphosphine-
[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-
2-ylidene][benzylidene]ruthenium dichloride. This ring
closing step follows the methodology developed by
Grubbs using catalysts based on ruthenium (P. Schwab,

                                     -16-

R.H. Grubbs, J.W. Ziller, J. Am. Chem. Soc., 1996, 118,
100; S.T. Nguyen, R.H. Grubbs, J.W. Ziller, J. Am.
Chem. Soc., 1993, 115, 9858; E.L.Dias, S.T. Nguyen,
R.H. Grubbs, J. Am. Chem. Soc., 1998, 63, 824). Other
5   metal catalysts for the construction of cyclic amines
are known in the art. Dihydroxylation using OsO$_4$ gives
the diol 12. The sulfonyl group in 12 is removed using
thiophenol giving the amino diol 14. In the first
scheme the reductive coupling of butyraldehyde to give
10   15 is shown, although outside the scope of the
invention. The coupling of different side chains is
described in more detail below. Swern oxidation
generates the β-amino ketone 16.

The aldehydes and ketones containing the second
15   amino group were synthesised as follows:
C-3 Side Chain 20:

20

Two step reductive amination between benzaldehyde 17a
and but-4-enylamine gives the amine 18. Protection of
18 as the trifluoroacetamide gives the alkene 19,
25   treatment with ozone gives the aldehyde 20 on reductive
work-up.

The hydroxy C3 side chain may be synthesised as
indicated below with an asymmetric hydroxylation
providing enantiomerically enriched material. The key
30   steps are the reductive amination of the aryl aldehyde
with allylamine 201 to give the secondary amine 202.
Protection of this either as its o-nitrobenzenesulfonyl
or trifluoroacetyl derivative 203 followed by
asymmetric hydroxylation to provide the diol 204.
35   Regioselective O-silylation and then acetylation of the

-17-

secondary alcohol will provide the acetate **205** which on desilylation and oxidation will give the required aldehyde **206**. Reductive coupling of the aldehyde then proceeds as described above.

C-2 Side Chains 25a and 25b

17a, Ar = Phenyl, or
17b, Ar = 2-Naphthalene;
R = Methyl, or Ethyl

Following a similar sequence described above reductive amination of benzaldehyde **17a** and 2-naphthylaldehyde **17b** with the acetal **21** gives the amines **22a** and **22b**. Protection of the amino group with trifluoroacetic anhydride gives the amides **23a** and **22b**. Acetal deprotection under acidic catalysis furnishes the aldehydes **24a** and **24b**.

Pyrrolidine Side Chains 31 and 33:

Reference is made to the following reaction scheme. *Trans*-4-Hydroxyproline **25** is protected with the tert-butyloxy carbonyl group (Boc) **26** before acid activation as the Weinreb amide and hydroxyl protection as the tert-butyldimethylsilyl ether (TBS) giving the known amide **27**. Organometallic addition to **27** with

-18-

phenyl magnesium bromide (PhMgBr) gives the ketone 28.
Reduction of the amide 27 with diisobutylaluminium
hydride gives the aldehyde 29. Carbonyl reduction of
28 and 29 generates the protected pyrrolidines 30 and
5   31. TBS removal followed by Swern oxidation generates
the Boc protected ketones 31 and 33.

An alternative synthesis of the pyrrolidine side
chains is as follows.
10   With reference to the following reaction scheme,
the starting material hydroxyproline 101 is bis-
protected and converted into the ester 102. Reduction -
oxidation to the aldehyde 103 followed by addition of
an aryl Grignard reagent will give the alcohol 104, as
15   a mixture of diastereoisomers, which is reduced using
Barton chemistry (e.g. conversion into the
thionocarbonate folowed by reduction using tributyltin
hydride) to give the pyrrolidine derivative 105. At
this stage the t-Boc group will be replaced by a
20   trifluoroacetate and desilylation and oxidation will
give the ketone 106. Reductive coupling of the ketone
then proceeds as described above.

-19-

Side Chain Coupling to Azepinyl Nucleus 14:

The side chains whose synthesis is described above are then coupled to the functionalised azepinyl nucleus 14 under one-pot reductive amination conditions. This furnishes the diols 34a-c and 36a,b. Swern oxidation of the secondary hydroxyl group and deprotection of the trifluoroacetamide 34a-c, or tert-butyloxycarbonyl 35a,b gives the azepines 35a-c and 37a,b.

-20-

The 5-fluoro analogues may be synthesised as follows:

Synthesis of 5-Fluoro Analogue:

Phthalide 1 is regio-selectively nitrated to give 38.
Reduction of the nitro group gives the aniline 39,
which is converted into the known 5-fluorophthalide 40.
Diiisobutylaluminium hydride reduction of the lactone
in 40 gives the lactol 41. Reductive amination of 41
with allylamine gives the amine 42, which is
chemo-selectively converted to its

-21-

2-nitrophenylsulfonyl derivative 43. Manganese dioxide
oxidation of 43 gives the aldehyde 44 which reacts with
cyclobutylmagnesium bromide to give the benzylic
alcohol 45. Oxidation giving the ketone 46 followed by
methylenation with Petasis's reagent gives the
dialkenyl cyclisation precursor 47. Ring closing
olefin metathesis with the imidazoyl based ruthenium
benzylidene catalyst gives the dihydroazepine 48.
Dihydroxylation with OsO_4 gives the diol 49, which is
converted into the amine 50. 50 is then coupled with
the acyclic side chains 20 and 24a,b under the one-pot
reductive amination conditions to give the diols 51a-c.
Oxidation, followed by trifluoroacetamide deprotection
gives the 4-fluoro bis-amines 52a-c.

An alternative (less preferred) synthetic pathway
to that described above is as follows. These pathways
may be generalized by the skilled person where
necessary.

For compounds where R_3 is as follows:

the following synthetic pathway may be employed.

Step a Reaction of the cyclobutyl lithium (or other organometallics) with the known lactone is conducted at -78°C, with slow inverse addition of the reagent.

Step b Reaction of the ketoalcohol with bromacetyl
bromide and pyridine (mole ratio 1:1:1), gives an
unstable bromoester; which is utilised immediately.

Steps c The bromoester is dissolved in acetonitrile at
room temperature and treated with triphenylphosphine.
After 3 days stirring at room temperature triethylamine
is added and after a further week the ε-lactone is
isolated.

Steps d The lactone may be reduced in one step, but the
better yields are achieved by use of a two step
protocol via the lactol.

Steps e The bis(tosylate) is prepared at -20°C warming
to room temperature to minimise formation of a cyclic
ether. Formation of the seven membered ring is
performed under high dilution conditions (0.1 mmolar)
in DMSO to minimise dimer formation. The methodology
is illustrated by the oxazolidinone protected amino
alcohol, but other protecting groups may be employed
such as carbonenzyloxy.

Steps f The diol moiety is installed by use of
Sharpless asymmetric dihydroxylation methodology using
the AD-mix α or a comparable reagent.

Steps g Oxidation of the diol is performed under mild
conditions using the Dess-Martin periodinane reagent.

Steps h The oxazolidinone ring is cleaved directly
under acidic or basic conditions. In the case where R
= H, the three step method indicated in the scheme is
the preferred method.

For compounds in which R_3 is as follows:

the same pathway as given above in the immediately

-24-

preceding section may be used except that a different
side chain is used in the N-alkylation step (step (e)).

The invention will now be illustrated by the following examples.

In the examples, flash column chromatography was performed using Merck silica gel (60H; 40-60μ, 230-240 mesh). Thin layer chromatography (TLC) was carried out using glass backed plates coated with Merck HF254/366 silica gel. The spots were visualised using ultraviolet radiation, treatment with basic permanganate solution, or acidic ethanolic anisaldehyde solution. Petroleum ether (Pet) was redistilled before use and refers to the fraction boiling between 40 and 60°C. Tetrahydrofuran was dried over sodium-benzophenone and was distilled prior to use. Dichloromethane was dried over CaH_2 and was distilled before use.

Mass spectra, either electron impact (EI), or chemical ionisation using ammonia (CI), were recorded by Val Boote using a Fisons VG Trio 200 spectrometer. High resolution mass spectra were recorded by Peter Kobryn on a Kratos Concept IS spectrometer. Microanalyses were performed using a Carlo-Erba combustion analyser for C, H and N. Infra-red spectra were recorded on a Genesis FTIR spectrometer on NaBr plates, either neat, or as evaporated films. Proton, proton-decoupled carbon and fluorine nuclear magnetic resonance spectra were recorded on either a Varian (400 MHz), Varian INOVA 300 (300 MHz), or a Varian Gemini 200 (200 MHz) spectrometer. Where applicable proton assignment was facilitated using correlation spectroscopy (COSY). Residual non-deuterated solvent was used as an internal standard and the chemical shifts are quoted in ppm down field from tetramethylsilane. Signal splitting patterns are

described as singlets (s), doublets (d), doublet of doublets (dd), doublet of double doublets (ddd), triplets (t), doublet of triplets (dt), quartets (q), or multiplets (m). The coupling constants (J) are

5   given in Hertz (Hz).

Example 1

N-Benzyl-N-(3-butenyl)amine **1**:

10   According to literature[79] at 0°C AlCl$_3$ (18.0 g, 0.135 mol, 1 eq.) in dry Et$_2$O (200 cm^3) was treated initially with LAH (5.12 g, 0.135 mol, 1 eq.) and then after 0.5h allyl cyanide (9.3 g, 0.135 mol, 1 eq.) was added dropwise. Stirring was maintained for 2 h at 0°C

15   before H$_2$O (20 cm^3) was added followed by 4 M NaOH (20 cm^3) and H$_2$O (60 cm^3). The solid residue was filtered, washing with Et$_2$O (2 x 50 cm^3). The volatile amine was stripped *in vacuo* with care and added directly to a solution of benzaldehyde (14 cm^3, 0.137 mol, 1.01 eq.)

20   in DCM (200 cm^3) with MgSO$_4$ (20 g). Stirring was continued at room temperature for 24 h. Filtration followed by solvent removal gave the imine, which was reduced directly. The imine in MeOH (100 cm^3) was treated portionwise with NaBH$_4$ (5.1 g, 0.134 mol, 1

25   eq.) and stirring was continued for 2 h. The reaction mixture was concentrated *in vacuo* and Et$_2$O (100 cm^3) and H$_2$O (100 cm^3) were added. The resultant aqueous phase was further extracted with Et$_2$O (2 x 100 cm^3) and the combined organic phases were dried over MgSO$_4$.

30   Filtration and solvent removal under reduced pressure

SUBSTITUTE SHEET (RULE 26)

gave **1** (5.9 g, 44%) as a yellow liquid. m/z (CI) 162 (MNH$_4$$^+$, 100%); δ_H (300 MHz, CDCl$_3$) 2.25 (2H, q, J 7.0 Hz, CH$_2$), 2.76 (2H, t, J 7.0 Hz, CH$_2$), 3.82 (2H, s, CH$_2$), 5.02-5.19 (2H, m, CH$_2$), 5.76-5.94 (1H, m, CH),

5   7.23-7.44 (5H, m, ArH).

Example 2

N-Benzyl-N-(3-butenyl)-2,2,2-trifluoroacetamide **2**:

10   At 0°C a solution of amine **1** (5.9 g, 36.65 mmol, 1 eq.) and TEA (25.0 cm^3, 179.37 mmol, 5 eq.) in DCM (100 cm^3) was treated with a solution of (CF$_3$CO)$_2$O (7.8 cm^3, 55.22 mmol, 1.5 eq.) added via a dropping funnel. The mixture was stirred for 3 h at 0°C to room temperature.

15   HO (100 cm) was added and the resultant aqueous phase was further extracted with DCM (2 x 100 cm^3). The combined organic extracts were dried over MgSO$_4$. Filtration, solvent removal under reduced pressure and purification by flash column chromatography (Pet:Et$_2$O;

20   9:1) gave **2** (6.42 g, 68%) as a yellow liquid. R_f = 0.3 (Pet:Et$_2$O; 9:1); m/z (CI) 275 (MNH$_4$$^+$, 100%), 258 (MH$^+$, 40%); found (EI) 257.1022, C$_{13}$H$_{14}$NOF$_3$ requires 257.1027 (-1.9 ppm); δ_H (300 MHz, CDCl$_3$) 2.23-2.42 (2H, m, CH$_2$), 3.34-3.45 (2H, m, CH$_2$), 4.62 (2H, s, CH$_2$), 4.71 (2H, s,

25   CH$_2$), 5.05-5.18 (2H, m, CH$_2$), 5.63-5.81 (1H, m, CH), 7.11-7.22 (5H, m, ArH); ^{1}H-NMR spectrum complicated due to restricted rotation.

Example 3

N-Benzyl-N-(3-oxopropyl)-2,2,2-trifluoroacetamide **3**:

At −78°C a solution of **2** (2.01 g, 7.82 mmol, 1 eq.) in

5   DCM (20 cm^3) was treated with a steady stream of ozone

gas for 0.5 h. At this point TLC analysis indicated

consumption of **2**. The excess ozone was purged under a

flow of oxygen and DMS (3 cm, 40.86 mmol, 5.2 eq.) was

added. The reaction mixture was warmed to room .

10   temperature and stirred for 15 h. Solvent removal *in*

vacuo and flash column chromatography (Pet:EtOAc; 4:1,

1% TEA) gave **3** (1.72 g, 85%) as a clear liquid. R_f =

0.2 (Pet:EtOAc; 4:1);); υ_{max} (neat/cm^{-1}) 3066, 3034,

2944, 2836, 2733, 1724, 1690, 1453, 1377, 1204, 1147;

15   m/z (CI) 277 (MNH$_4^+$, 100%), 260 (MH$^+$, 100%); found

277.1167, C$_{12}$H$_{12}$NO$_2$F$_3$·NH$_4$ requires 277.1164 (+1.1 ppm);

δ_H (300 MHz, CDCl$_3$) 2.75-2.84 (2H, m, CH$_2$), 3.61 (2H,

t, J 6.5 Hz, CH$_2$), 3.76 (2H, t, J 7.0Hz, CH$_2$), 4.66

(2H, s, CH$_2$), 4.73 (2H, s, CH$_2$), 7.25-7.47 (5H, m,

20   ArH), 9.74 (1H, s(br), CHO); ^{1}H-NMR spectrum

complicated due to restricted rotation (60:40).

Example 4

25   *N-Allyl-N-benzylamine* **4**:

A mixture of benzaldehyde (9.8 cm^3, 96.0 mmol, 1 eq.),

allylamine (10.8 cm^3, 143.9 mmol, 1.5 eq.) and MgSO$_4$

(20 g) in DCM (100 cm^3) were stirred together at room

temperature for 15 h. Filtration and solvent removal

under reduced pressure gave the imine (*ca.* 96 mmol) which was dissolved in MeOH (100 cm^3). At room temperature NaBH$_4$ (3.65 g, 96.1 mmol, 1 eq.) was added in portions. Stirring was continued for 2 h before

5   approximately half the solvent was removed under reduced pressure. Et$_2$O (100 cm^3) and H$_2$O (100 cm^3) were added and the mixture was basified with 1 M NaOH (*ca.* pH 12). The aqueous layer was further extracted with Et$_2$O (2 x 100 cm^3) and the combined ethereal

10 extracts were dried over MgSO$_4$. Filtration and solvent removal *in vacuo* afforded the amine **4** (8.94 g, 64%) as a clear liquid. m/z (CI) 148 (MH$^+$, 100%); δ_H (200 MHz, CDCl$_3$) 1.5 (1H, s(br), NH), 3.32 (2H, d, *J* 6.5 Hz, CH$_2$), 4.82 (2H, s, CH$_2$), 5.07-5.32 (2H, m, CH$_2$), 5.82-

15 6.08 (1H, m, CH), 7.19-7.45 (5H, m, ArH).

Example 5

N-Allyl-N-benzyl-2-nitrophenylsulfonamide 5:

20 At room temperature a mixture of **4** (950 mg, 6.46 mmol, 1 eq.), TEA (1.8 cm^3, 12.91 mmol, 2 eq.) and DMAP (*ca.* 2 mg) in DCM (20 cm^3) was treated with NsCl (1.43 g, 6.45 mmol, 1 eq.). Stirring was continued for 3 h before H$_2$O (50 cm^3) and Et$_2$O (50 cm^3) were added. The

25 resultant aqueous phase was extracted further with Et$_2$O (2 x 50 cm^3) and the total organic extracts were dried over MgSO$_4$. Filtration followed by solvent removal *in vacuo* afforded the crude sulfonamide which was purified by flash column chromatography (Pet:EtOAc; 5:1) to give

5 (1.63 g, 76%) as a viscous clear oil. R_f = 0.25

(Pet:EtOAc; 5:1); m/z (CI) 350 (MNH$_4^+$, 100%); found

350.1176, $C_{16}H_{16}N_2O_4S \cdot NH_4$ requires 350.1174 (+0.6 ppm);

δ_H (300 MHz, CDCl$_3$) 3.77 (2H, d, J 6.5 Hz, CH$_2$), 4.45

5   (2H, s, CH$_2$), 4.95-5.08 (2H, m, CH$_2$), 5.50 (1H, ddd

app. qt, J 6.5, 10.0, 17.0 Hz, CH), 7.19-7.25 (5H, m,

ArH), 7.51-7.65 (3H, m, ArH), 7.93 (1H, d, J 7.5 Hz,

ArH); δ_C (75 MHz, CDCl$_3$) 49.2, 50.3, 119.6, 124.2,

127.8, 128.3, 128.6, 130.9, 131.7, 131.8, 133.5, 134.0,

10   135.3, 147.8.

Example 6

N-Benzyl-N-(2-oxoethyl)-2-nitrophenylsulfonamide 6:

15   A solution of 5 (1.11 g, 3.34 mmol, 1 eq.) in DCM (25

cm^3) at -78°C was treated with a steady stream of ozone

gas until TLC analysis indicated no remaining starting

material (ca. 0.5 h). The excess ozone was purged

under a flow of oxygen before DMS. (4.0 cm^3, 54.47 mmol,

20   16 eq.) was added and the mixture was allowed to warm

to room temperature and stirred for 15 h. Evaporation

of the solvent under reduced pressure followed by flash

·column chromatography (Pet:EtOAc; 1:1) gave 6 (1.04 g,

92 %) as a colourless solid. For microanalysis 6 was

25   recrystallised from EtOAc and petroleum ether. R_f =

0.25 (streak) (Pet:EtOAc; 5:1); υ_{max} (CDCl3/cm^{-1}) 3055,

2986, 2831, 1735, 1546, 1371, 1266, 1166; m/z (FAB) 690

(M$_2$Na$^+$, 90%); δ_H (300 MHz, CDCl3) 4.11 (2H, s, CH$_2$),

4.65 (2H, s, CH$_2$), 7.25-7.38 (5H, m, ArH), 7.65-7.74

(3H, m, ArH), 8.11 (1H, d, J 7.5 Hz, ArH), 9.39 (1H, s, CHO); δ_C (75 MHz, CDCl3) 52.6, 55.5, 124.3, 128.6, 128.7, 128.9, 130.9, 131.9, 133.0, 133.8, 134.1, 147.0, 196.4; found C, 53.6; H, 4.5; N, 8.4; S, 9.6%;

5    $C_{15}H_{14}N_2O_5S$ requires, C, 53.9; H, 4.2; N, 8.4; S, 9.6%.

Example 7

2-(tert-Butyldimethylsilanyloxymethyl)-N-methoxy-N-

10   *methylbenzamide* **7**:

At 0°C under argon a 2 M solution of AlMe3 in hexane (32 cm³, 64.5 mmol, 2 eq.) was added dropwise over *ca.* 0.25 h to a suspension of HCl·NH(OMe)Me (6.29 g, 64.5 mmol, 2 eq.) in DCM (60 cm³). During the addition of

15   0.5 eq. of AlMe3 a vigorous gas evolution ensued. The now clear mixture was stirred for 1 h at 0°C before a solution of phthalide (isobenzofuran) (4.32 g, 32.2 mmol, 1 eq.) in DCM (20 cm³) was added. Stirring was maintained for 7 h during which time room temperature

20   was reached. Saturated sodium potassium tartrate solution (100 cm³) was cautiously added. The resultant aqueous layer, obtained after separation was further extracted with DCM (2 x 100 cm³). The combined organic extracts were washed with sat. brine solution (100 cm³)

25   and dried over Na2SO4. Filtration followed by solvent removal *in vacuo* gave the crude Weinreb amide which was directly *O*-protected in order to minimise re-lactonisation. Thus, at room temperature the crude amide (*ca.* 32.2 mmol, 1 eq.) was dissolved in DCM (50

30   cm³) and treated with TBDMS-Cl (4.9 g, 32.2 mmol, 1

eq.) and imidazole (4.4 g, 64.5 mmol, 2 eq.). Stirring
was continued for 15 h. Water (100 cm^3) and DCM (50
cm^3) were added and the resultant aqueous layer was
further extracted with DCM (100 cm^3). The combined

5   organic extracts were dried over MgSO$_4$ before
filtration and solvent removal *in vacuo* gave the crude
product. Purification by flash column chromatography
(Pet:EtOAc; 5:1 → Pet:EtOAc; 3:1) gave the Weinreb
amide **7** (5.93 g, 60%) as a clear liquid. R_f = 0.3

10   (Pet:EtOAc; 4:1); υ_{max} (neat/cm^{-1}) 3064, 2954, 2893,
2857, 1650, 1463, 1416, 1383, 1257, 1119, 1081; m/z
(CI) 310 (MH$^+$, 100%); found 310.1835, C$_{16}$H$_{27}$NO$_3$Si·H
requires 310.1838 (+0.9 ppm); $\square_H$ (300 MHz, CDCl$_3$) 0.00
(6H, s, CH$_3$), 0.84 (9H, s, CH$_3$), 3.19 (3H, s, CH$_3$),

15   3.44 (3H, s(br), CH$_3$), 4.69 (2H, s, CH$_2$), 7.16–7.22
(2H, m, ArH), 7.31 (1H, dt, J 2.5, 7.5 Hz, ArH), 7.45
(1H, d, J 7.5 Hz, ArH); δ_C (75 MHz, CDCl$_3$) -5.4, 18.4,
25.9, 33.6, 61.0, 62.5, 126.4, 126.8, 129.3, 132.7,
138.8, 169.7.

20

Example 8

[2-tert-Butyldimethylsilanyloxymethyl)phenyl]cyclo-
butylmethanone **8**:

25   At -78°C under argon ^{t}BuLi 1.7 M in pentane (16 cm^3,
27.31 mmol, 2 eq.) was added in a dropwise fashion to a
solution of cyclobutyl bromide (1.3 cm^3, 13.66 mmol, 1
eq.) in THF (15 cm^3). The resultant yellow solution
was stirred for 1 h at -78°C before adding *via* cannula

to a cooled (-78°C) solution of the Weinreb amide **7**

(2.11 g, 6.83 mmol, 0.5 eq.) in THF (30 cm³). Stirring

was continued for 1 h. Saturated NH₄Cl solution (50

cm³) was added and the mixture was warmed to room

5   temperature. Extraction with ether (3 x 50 cm³) and

drying of the combined organic extracts over MgSO₄ gave.

the crude cyclobutane after filtration and solvent

removal under reduced pressure. Purification by flash

column chromatography (Pet:EtOAc; 8:1 → Pet:EtOAc; 5:1)

10 afforded **8** (1.1 g, 59%) as a clear oil. R_f = 0.55

(Pet:EtOAc; 5:1).

Example 9

15 tert-*Butyl-[2-(1-cyclobutylvinyl)benzyloxy]dimethyl-*
silane **9**:

Under N₂ in foil covered apparatus a mixture of **8** (476

mg, 1.57 mmol, 1 eq.) and Cp₂TiMe₂[73] (700 mg, 3.35

mmol, 2.1 eq.) in THF (20 cm³) were heated to reflux

20 for 15 h. Petroleum ether (100 cm³) was added and the

reaction mixture was filtered through Celite®. The

residue was washed with petroleum ether (2 x 50 cm³)

before silica (*ca.* 5 g) was added and the solvent

removed under reduced pressure. Purification by flash

25 column chromatography (Pet:EtOAc; 19:1) gave **9** (434 mg,

92%) as a clear oil. R_f = 0.25 (Pet:EtOAc; 19:1); m/z

(CI) 320 (MNH₄⁺, 5%), 303 (MH⁺, 10%), 171 (100%); found

(EI) 302.2062 C₁₉H₃₀OSi requires 302.2066 (-1.3 ppm);

δ_H (300 MHz, CDCl$_3$) -0.08 (6H, s, CH$_3$), 0.84 (9H, s, CH$_3$), 1.55-1.67 (1H, m, CH$_2$), 1.69-2.01 (5H, m, CH$_2$), 3.10 (1H, pent, J 8.0 Hz, CH), 4.58 (2H, s, CH$_2$), 4.79 (1H, d, J 1.5 Hz, CH$_2$), 5.06 (1H, d, J 1.5 Hz, CH$_2$),

5   6.94 (1H, d, J 7.5 Hz, ArH), 7.09 (1H, t, J 7.5 Hz, ArH), 7.17 (1H, t, J 7.5 Hz, ArH), 7.44 (1H, d, J 7.5 Hz, ArH); δ_C (75 MHz, CDCl$_3$) -5.3, 17.6, 18.4, 25.9, 28.0, 42.0, 62.6, 112.1, 126.2, 126.7, 127.9, 138.0, 140.2, 151.9.

10

Example 10

[2-(1-Cyclobutylvinyl)phenyl]methanol 10:

At room temperature a 1 M solution of TBAF (0.9 cm^3,

15   0.90 mmol, 1 eq.) was added dropwise to a solution of **9** (269 mg, 0.89 mmol, 1 eq.) in THF (10 cm^3) and stirring was continued for 2 h. Et$_2$O (15 cm^3) and H$_2$O (25 cm^3) were added and the resultant aqueous layer was extracted with Et$_2$O (2 x 25 cm^3). The combined

20   ethereal extracts were dried over MgSO$_4$, filtered and the solvent removed under reduced pressure. Purification by flash column chromatography (Pet:EtOAc; 19:1 → Pet:EtOAc; 5:1) afforded the *title compound* **10** (139 mg, 83%) as a clear oil. R_f = 0.3 (Pet:EtOAc;

25   5:1); m/z (CI) 206 (MNH$_4^+$, 15%), 189 (MH$^+$, 10%), 171 (100%); found 189.1277, C$_{13}$H$_{16}$O·H requires 189.1279 (-1.1 ppm); δ_H (300 MHz, CDCl$_3$) 1.55-1.67 (1H, m, CH$_2$), 1.71-2.01 (5H, m, CH$_2$), 3.13 (1H, pent, J 8.0 Hz, CH),

4.54 (2H, s, CH$_2$), 4.83 (2H, d, J 1.25 Hz, CH$_2$), 5.11 (1H, dd, J 1.25 Hz, CH$_2$), 6.99 (1H, d, J 7.0 Hz, ArH), 7.11-7.22 (2H, m, ArH), 7.36 (1H, d, J 7.25 Hz, ArH); δ$_C$ (75 MHz, CDCl$_3$) 17.6, 27.9, 42.1, 63.2, 112.4,

5   127.05, 127.1, 128.0, 128.5, 137.7, 141.7, 152.2.

Example 11

2-(1-Cyclobutylvinyl)benzaldehyde **11**:

10   A solution of **10** (1.90 g, 10.11 mol, 1 eq.) in DCM (60 cm^3) was treated with pre-dried MnO$_2$ (4.40 g, 50.61 mol, 5 eq.) at room temperature and stirring was continued for 2 days. The reaction mixture was then filtered through Celite® and the residue was washed

15   with DCM (2 x 50 cm^3). Concentration *in vacuo* and purification by flash column chromatography (Pet:EtOAc; 19:1) gave the aldehyde **11** (1.75 g, 93%) as a clear liquid. R_f = 0.3 (Pet:EtOAc; 19:1); υ_{max} (neat, cm^{-1}) 3084, 2976, 2940, 2864, 2748, 1695, 1596, 1479, 1446,

20   1391; m/z (CI) 264 (MNH$_4^+$, 15%), 187 (MH$^+$, 60%), 169 (100%); found 187.1121, C$_{13}$H$_{14}$O·H requires 187.1122 (−0.5 ppm); □$_H$ (300 MHz, CDCl$_3$) 1.66-1.77 (1H, m, CH$_2$), 1.79-2.13 (5H, m, CH$_2$), 3.31 (1H, pent, J 8.0 Hz, CH), 4.96 (1H, d, J 1.5 Hz, CH$_2$), 5.37 (1H, d, J 1.5 Hz,

25   CH$_2$), 7.25 (1H, d, J 7.5 Hz, ArH), 7.37 (1H, t, J 7.5 Hz, ArH), 7.52 (1H, t, J 7.5 Hz, ArH), 7.93 (1H, d, J 7.5 Hz, ArH), 10.18 (1H, s, CHO); δ$_C$ (75 MHz, CDCl$_3$) 17.6, 27.7, 42.2, 115.5, 127.2, 127.3, 128.9, 133.2, 133.7, 146.2, 149.2, 192.1.

36

Example 12

Allyl-[2-(1-cyclobutylvinyl)benzyl]amine **12**:

5   A mixture of aldehyde **11** (540 mg, 2.90 mmol, 1 eq.) and

$MgSO_4$ (*ca.* 5 g) in DCM (30 cm^3) were treated at room

temperature with allylamine (0.45 cm^3, 6.00 mmol, 2

eq.). The reaction mixture was stirred for 24 h and

filtered. Solvent removal gave the crude imine. At

10   room temperature the imine (*ca.* 2.90 mmol, 1 eq.) was

dissolved in MeOH (20 cm^3) and $NaBH_4$ (164 mg, 4.33

mmol, 1.5 eq.) was added portionwise. After stirring

for 2 h DCM (50 cm^3) and H_2O (50 cm^3) were added and

the mixture was basified with 2.5 M NaOH (*p*H 10). The

15   resultant aqueous phase was further extracted with DCM

(3 x 50 cm^3) and the combined organics were dried over

$MgSO_4$. Filtration and solvent removal *in vacuo* gave

127 (600 mg, 91%) as a yellow oil which was used

without further purification. m/z (CI) 288 (MH^+,

20   100%); δ_H (300 MHz, $CDCl_3$) 1.39-1.51 (1H, s(br), NH),

1.68-1.79 (1H, m, CH_2), 1.87-2.11 (5H, m, CH_2), 3.21

(1H, pent, *J* 8.0 Hz, CH), 3.25 (2H, dt, *J* 0.5, 6.5 Hz,

CH_2), 3.75 (2H, s, CH_2), 4.93 (1H, s, CH_2), 5.07-5.25

(2H, m, CH_2), 5.19 (1H, s, CH_2), 5.84-6.03 (1H, m, CH),

25   7.04-7.08 (1H, m, ArH), 7.16-7.29 (2H, m, ArH), 7.39-

7.43 (1H, m, ArH); δ_C (75 MHz, $CDCl_3$) 17.6, 28.0, 42.2,

50.6, 51.9, 53.3, 112.0, 115.6, 126.3, 126.8, 128.6,

128.7, 136.9, 137.0, 141.8, 152.7.

Example 13

N-*Allyl*-N-*[2-(1-cyclobutylvinyl)benzyl]-2-
nitrophenylsulfonamide* **13**:

5   A mixture of the amine **12** (200 mg, 0.881 mmol, 1 eq.),

TEA (0.18 cm^3, 1.291 mmol, 1.5 eq.), 2-NsCl (215 mg,

0.970 mmol, 1.1 eq.) and a catalytic amount of DMAP

(*ca.* 2 mg) in DCM (10 cm^3) were stirred at room

temperature for 3 h. Et_2O (25 cm^3) and H_2O (25 cm^3)

10   were added and the resultant aqueous layer was further

extracted with Et_2O (2 x 15 cm^3). The combined organic

extracts were dried over $MgSO_4$. Filtration, solvent

removal under reduced pressure followed by flash column

chromatography (Pet:EtOAc; 3:1) gave the *title compound*

15   **13** (285 mg, 79%) as a clear viscous oil. R_f = 0.3

(Pet:EtOAc; 3:1); m/z (CI) 430 (MNH_4^+, 15%), 413 (MH^+,

5%), 383 (30%), 228 (50%), 171 (100%); found

413.1528,$C_{22}H_{24}N_2O_4S \cdot H$ requires 413.1535 (-1.7 ppm); δ_H

(300 MHz, $CDCl_3$) 1.63-1.78 (1H, m, CH_2), 1.82-2.11 (5H,

20   m, CH_2), 3.16 (1H, pent, J 8.25 Hz, CH), 3.94 (2H, d, J

6.25 Hz, CH_2), 4.61 (2H, s, CH_2), 4.88 (1H, s, CH_2),

5.01-5.12 (2H, m, CH_2), 5.22 (1H, t(br), J 1.5 Hz,

CH_2), 5.61 (1H, tq, J 6.25 Hz, CH), 7.04-7.11 (1H, m,

ArH), 7.18-7.26 (2H, m, ArH), 7.35-7.41 (1H, m, ArH),

25   7.63-7.76 (3H, m, ArH), 8.04 (1H, d, J 7.5 Hz, ArH); δ_C

(75 MHz, $CDCl_3$) 17.6, 28.0, 42.0, 48.1, 49.6, 112.8,

38

119.0, 124.1, 126.8, 127.1, 127.2, 128.6, 131.0, 131.6,
132.0, 132.2, 133.4, 134.0, 141.8, 143.8, 151.6.

Example 14

5

*5-Cyclobutyl-2-(2-nitrophenylsulfonyl)-2,3-dihydro-1H-
benzo[c]azepine* **14**:

The dialkenyl sulfonamide **13** (885 mg, 2.12 mmol, 1 eq.)
and Grubbs catalyst (90 mg, 0.106 mmol, 5 mol%) in

10 degassed DCM (100 cm^3) were heated to reflux for 18 h.
The Grubb's catalyst used was tricyclohexylphosphine-
[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-
ylidene][benzylidine]ruthenium(IV)dichloride, available
from Strum Chemicals Inc., Catalogue No. 77-7770. The

15 reaction mixture was cooled to room temperature and
silica (*ca.* 3 g) was added. Solvent removal under
reduced pressure and purification by flash column
chromatography (Pet:EtOAc; 3:1) gave the *title compound*
14 (780 mg, 96%) as a clear viscous oil. R_f = 0.25

20 (Pet:EtOAc; 3:1); m/z (CI) 385 (MH$^+$, 5%), 355 (20%),
198 (90%), 94 (100%); found 385.1224, $C_{20}H_{20}N_2O_4S \cdot H$
requires 385.1222 (+0.5 ppm); δ_H (300 MHz, CDCl$_3$) 1.72-
1.82 (1H, m, CH$_2$), 1.83-2.04 (3H, m, CH$_2$), 2.13-2.24
(2H, m, CH$_2$), 3.49 (1H, pent, *J* 8.0 Hz, CH), 3.67 (2H,

25 d, *J* 7.5 Hz, CH$_2$), 4.19 (2H, s, CH$_2$), 5.90 (1H, dt, *J*
2.0, 7.5 Hz, CH), 7.25-7.32 (2H, m, ArH), 7.35-7.42
(2H, m, ArH), 7.64-7.77 (3H, m, ArH), 8.05 (1H, dd, *J*
2.0, 5.5 Hz, ArH); δ_C (75 MHz, CDCl$_3$) 17.8, 28.4, 39.5,

43.0, 49.2, 116.9, 124.0, 126.1, 128.0, 129.8, 130.5,
131.5, 132.9, 133.2, 133.3, 139.9, 148.2, 151.0.

Example 15a

5

5-Cyclobutyl-2-(2-nitrophenylsulfonyl)-2,3,4,5-
tetrahydro-1H-benzo[c]azepine-4,5-diol **15**:

At room temperature the alkene **14** (120 mg, 0.313 mmol,

1 eq.) was dissolved in acetone (5 cm^3) and H_2O (2.5

10   cm^3) and NMO (40 mg, 0.341 mmol, 1.1 eq.) were added.

OsO_4 (8 mg, 0.0315 mmol, 10 mol%) was then added to the

vigourously stirred mixture. Stirring was continued

for 18 h. DCM (15 cm^3) and H_2O (15 cm^3) were added and

the mixture was acidified with 3 M HCl (*pH* 2). The

15   aqueous phase was further extracted with DCM (3 x 15

cm^3) and the combined organics were dried over $MgSO_4$.

Filtration, solvent removal *in vacuo* followed by flash

column chromatography (Pet:EtOAc; 2:1) gave **15** (104 mg,

80%) as an amorphous grey solid. The diol **15** was

20   further purified by reprecipitation from Et_2O and

petroleum ether. R_f = 0.3 (Pet:EtOAc; 1:1); υ_{max}

($CDCl_3$, cm^{-1}) 3540, 3093, 2982, 2940, 2867, 1590, 1545,

1445, 1371, 1352, 1164; m/z (CI) 436 (MNH_4^+, 10%), 419

(MH^+, 5%), 389 (20%), 232 (40%), 94 (100%); found

25   419.1274, $C_{20}H_{22}N_2O_6S \cdot H$ requires 419.1277 (-0.7 ppm);

δ_H (300 MHz, $CDCl_3$) 1.29 (1H, m, CH_2), 1.78-1.90 (3H,

m, CH_2), 2.13-2.38 (2H, m, CH_2), 2.49 (1H, d, *J* 9.25

Hz, OH), 2.91 (1H, pent, J 8.0 Hz, CH), 3.22 (1H, s,
OH), 3.53 (1H, dd, J 1.0, 15.0 Hz, CH$_2$), 3.86 (1H, m,
CH), 4.03 (1H, ddd, J 2.0, 4.0, 15.0 Hz, CH$_2$), 4.46
(1H, d, J 16.0 Hz, CH$_2$), 4.83 (1H, dd, J 2.0, 16.0 Hz,
5   CH$_2$), 7.23-7.26 (2H, m, ArH), 7.36-7.40 (1H, m, ArH),
7.67-7.81 (3H, m, ArH), 7.86 (1H, d, J 7.5 Hz), 8.11
(1H, dd, J 2.0, 7.0 Hz, ArH); δ_C (75 MHz, CDCl$_3$) 17.5,
21.6, 21.8, 39.3, 50.9, 54.2, 72.5, 79.2, 124.2, 127.6,
128.2, 129.2, 130.2, 131.4, 131.7, 132.2, 132.8, 133.9,
10   140.8, 147.9.

Example 15b

*5-Cyclobutyl-2-(2-nitrophenylsulfonyl)-2,3,4,5-
tetrahydro-1H-benzo[c]azepine-4R,5R-diol* **15**:

15   At 5°C a mixture of dihydroazepine **14** (96 mg, 0.25
mmol, 1 eq.), AD-mix-β (180 mg) and MeSO$_2$NH$_2$ (24 mg,
0.25 mmol, 1 eq.) in ^{t}BuOH (1 cm^3) and H$_2$O (1 cm^3) were
stirred for 2 days. Saturated Na$_2$SO$_3$ (5 cm^3) and DCM
(10 cm^3) were added and the mixture was partitioned
20   vigorously for 1 h. The resultant aqueous phase was
further extracted with DCM (3 x 10 cm^3) and the
combined organic phases were dried over MgSO$_4$.
Filtration, solvent removal and purification by flash
column chromatography (Pet:EtOAc; 1:1) afforded **14** (41
25   mg, 43%) and the diol **15** (52 mg, 50%) whose data was in
agreement to that reported above.

Example 16

5-Cyclobutyl-2,3,4,5-tetrahydrobenzo[c]azepine-4,5-diol
16:

At room temperature a mixture of nosylate **15** (256 mg,
0.61 mmol, 1 eq.) and K_2CO_3 (296 mg, 2.14 mmol, 3.5

5   eq.) in DMF (15 cm^3) was treated with PhSH (80 µL, 0.78
mmol, 1.3 eq.). Stirring was continued at room
temperature for 24 h. Ethyl acetate (25 cm^3) and water
(25 cm^3) was added and the resultant aqueous layer was
further extracted with EtOAc (5 x 25 cm^3). The

10 combined organic extracts were dried over $MgSO_4$.
Filtration followed by solvent removal and column
chromatography (EtOAc:MeOH; 3:1, 1% TEA) afforded the
diol **16** (122 mg, 86%) as an amorphous colourless solid.
R_f = 0.25 (EtOAc:MeOH; 3:1, 1% TEA); m/z (CI) 234 (MH$^+$,

15 100%); found 234.1498, $C_{14}H_{19}NO_2$·H requires 234.1494
(+1.7 ppm); δ_H (300 MHz) 1.26–1.38 (1H, m, CH_2), 1.69–
1.88 (3H, m, CH_2), 2.07–2.28 (2H, m, CH_2), 2.81–2.94
(1H, m, CH), 3.05 (1H, d, *J* 13.5 Hz, CH_2), 3.18 (1H,
dd, *J* 3.5, 13.5 Hz, CH_2), 3.66 (1H, d, *J* 3.5 Hz, CH),

20 3.84 (1H, d, *J* 15.0 Hz, CH_2), 4.00 (1H, d, *J* 15.0 Hz,
CH_2), 7.01 (1H, d, *J* 7.5 Hz, ArH), 7.16 (1H, t, *J* 7.5
Hz, ArH), 7.28 (1H, t, *J* 7.5 Hz, ArH), 7.80 (1H, d, *J*
7.5 Hz, ArH); δ_C (75 MHz) 17.6, 21.6, 21.8, 39.7, 51.9,
55.8, 73.2, 79.8, 126.9, 127.1, 129.2, 129.5, 136.3,

25 141.7.

Example 17

N-Benzyl-N-[2-(5-cyclobutyl-4,5-dihydroxy-1,3,4,5-
tetrahydrobenzo[c]azepin-2-yl)ethyl]-2-nitro-
5   *benzenesulfonamide* **17**:

At room temperature **16** (122 mg, 0.524 mmol, 1 eq.) and
the aldehyde **6** (see Example 6) (350 mg, 1.048 mmol, 2
eq.) in MeOH (5 cm) were treated with $NaBH_3CN$ (33 mg,
0.525 mmol, 1 eq.) and conc. HCl (1 drop). The mixture
10   was stirred for 15 h before EtOAc (25 cm^3) and H_2O (25

cm^3) were added. The pH was adjusted with 1 M NaOH to
ca. 12 and the resultant aqueous layer was further
extracted with EtOAc (2 x 25 cm^3) and DCM (3 x 25 cm^3).
The combined organic extracts were dried over $MgSO_4$ and
15   filtered. Silica (*ca.* 2.5 g) was added and the solvent
was removed *in vacuo*. Purification by flash column
chromatography (Pet:EtOAc; 1:1; 1% TEA → EtOAc; 1% TEA)
gave the adduct **17** (189 mg, 66%) as a viscous yellow

oil. R_f = 0.2 (Pet:EtOAc; 1:1);); υ_{max} ($CDCl_3/cm^{-1}$)
20   3468, 3065, 2940, 2867, 1544, 1455, 1370, 1162; m/z

(CI) 552 (MH^+, 2%), 363 (10%), 108 (100%); found
552.2172, $C_{29}H_{33}N_3O_6S\cdot H$ requires 552.2168 (+0.7 ppm);

δ_H (300 MHz, $CDCl_3$) 1.19-1.31 (1H, m, CH_2), 1.57-1.77
(3H, m, CH_2), 2.05-2.22 (2H, m, CH_2), 2.50-2.62 (2H, m,
25   CH_2), 2.71 (1H, pent, *J* 8.5 Hz, CH), 2.82-2.93 (2H, m,
CH_2), 3.31 (1H, ddd, *J* 5.0, 8.5, 15.0 Hz, CH_2), 3.38

(1H, dd, *J* 5.5, 15.0 Hz, CH2), 3.44 (1H, dd, *J* 7.5,

15.0 Hz, CH2), 3.58 (1H, d, *J* 3.5 Hz, CH), 3.69 (1H, d,

J 15.0 Hz, CH2), 6.91 (1H, d, *J* 7.5 Hz, ArH), 7.10 (1H,

dt, *J* 1.5, 7.5 Hz, ArH), 7.18-7.31 (6H, m, ArH), 7.53-

5   7.67 (3H, m, ArH), 7.73 (1H, dd, *J* 1.5, 8.0 Hz, ArH),

7.95 (1H, d, *J* 8.0 Hz, ArH); δ_C (100 MHz, CDCl3) 17.7,

21.7, 21.8 (CH2), 39.6 (CH), 45.5, 52.2, 57.5, 60.2,

63.0 (CH2), 73.1 (CH), 79.3 (C-quat), 124.2, 126.8,

127.2, 128.1, 128.15, 128.7, 128.8, 130.2, 130.8, 131.6

10 (CH), 133.1 (C-ipso), 133.4 (CH), 134.5, 135.1, 141.4,

147.8 (C-ipso).

Example 18

15 *N-Benzyl-N-[2-(5-cyclobutyl-5-hydroxy-4-oxo-1,3,4,5-*
tetrahydrobenzo[c]azepin-2-yl)ethyl]-2-nitro-
benzenesulfonamide **18**:

A solution of (COCl)2 (42 μL, 0.481 mmol, 4 eq.) in DCM

(1 cm3) was treated at -78°C with DMSO (60 μL, 0.846

20 mmol, 7 eq.). Stirring was continued for 0.25 h before

a solution of 17 (60 mg, 0.109 mmol, 1 eq.) in DCM (1

cm3) was added in a dropwise fashion. Additionally,

the flask was washed with DCM (1 cm3). The reaction

mixture was stirred for 2 h during which time the

25 temperature reached -10°C. TEA (100 □L, 0.718 mmol, 6

eq.) was added to the reaction mixture. Stirring was

44

continued for x h before H$_2$O (20 cm^3) and Et$_2$O (20 cm^3) were added. The resultant aqueous layer was further extracted with Et$_2$O (4 x 20 cm^3) and the combined organic extracts were dried over MgSO$_4$. Filtration followed by solvent removal and purification by flash column chromatography (Pet:EtOAc; 3:1, 1% TEA → Pet:EtOAc; 1:1, 1% TEA) afforded **18** (46 mg, 77%) as a yellow oil. R_f = 0.2 (Pet:EtOAc; 3:1, 1% TEA);); υ_{max} (neat/cm^{-1}) 3466, 3065, 2936, 2861, 1698, 1544, 1454, 1369, 1163; m/z (CI) 550 (MH$^+$, 20%), 363 (40%), 106 (90%), 94 (100%); found 550.2021, C$_{29}$H$_{31}$N$_3$O$_6$S·H requires 550.2012 (+1.6 ppm); δ_H (300 MHz,, CDCl$_3$) 1.49-1.62 (1H, m, CH$_2$), 1.65-1.88 (4H, m, CH$_2$), 2.22 (1H, pent, J 9.0 Hz, CH), 2.33 (2H, t, J 7.0 Hz, CH$_2$), 3.34-3.39 (3H, m, CH, CH$_2$), 3.38 (1H, d, J 15.0 Hz, CH$_2$), 3.64 (1H, d, J 15.0 Hz, CH$_2$), 3.76 (1H, d, J 16.0 Hz, CH$_2$), 4.04 (1H, d, J 16.0 Hz, CH$_2$), 4.50 (2H, s, CH$_2$), 4.54 (1H, s(br), OH), 6.91 (1H, d, J 7.5 Hz, ArH), 7.10 (1H, dt, J 1.5, 7.5 Hz, ArH), 7.18-7.31 (6H, m, ArH), 7.53-7.67 (3H, m, ArH), 7.73 (1H, dd, J 1.5, 8.0 Hz, ArH), 7.95 (1H, dd, J 1.0, 8.0 Hz, ArH); δ_C (75 MHz, CDCl$_3$) 17.0, 21.3, 21.6, 41.6, 44.8, 51.0, 52.1, 59.5, 63.5, 84.1, 124.2, 127.3, 127.5, 127.6, 128.1, 128.2, 128.7, 129.9, 130.8, 131.6, 133.4, 133.6, 133.8, 135.4, 138.3, 148.1, 206.8.

Example 19

2-[2-(benzylamino)ethyl]-5-cyclobutyl-5-hydroxy-
1,3,4,5-tetrahydrobenzo[c]azepin-4-one **19**:

5 At room temperature a solution **18** (260 mg, 0.474 mmol,

1 eq.) in DMF (5 cm^3) was treated with K_2CO_3 (212 mg,

1.534 mmol, 3.2 eq.) and PhSH (60 μL, 0.584 mmol, 1.2

eq.). Stirring was continued for 18 h before H_2O (25

cm^3) and EtOAc (25 cm^3) were added. The resultant

10 aqueous layer was extracted with EtOAc (5 x 15 cm^3) and

the combined organic layers were dried over $MgSO_4$. The

crude amine obtained after filtration and solvent

removal *in vacuo* was purified by flash column

chromatography (Pet:EtOAc; 1:1, 1% TEA → Pet:EtOAc;

15 1:2, 1% TEA) which gave the *title compound* **19** (90 mg,

52%) as a yellow oil. R_f = 0.15 (Pet:EtOAc; 1:1, 1%

TEA); υ_{max} (neat/cm^{-1}) 3454, 3054, 2934, 2855, 1692,

1453; m/z (CI) 365 (MH^+, 80%), 347 ($M-OH^+$, 30%), 108

(100%), 74 (80%); found 365.2220, $C_{23}H_{28}N_2O_2 \cdot H$ requires

20 365.2229 (-2.5 ppm); δ_H (300 MHz, $CDCl_3$) 1.40-1.48 (1H,

m, CH_2), 1.58-1.76 (4H, m, CH_2), 2.08-2.16 (1H, m,

CH_2); 2.48 (2H, t, J 6.0 Hz, CH_2), 2.71 (2H, t, J 6.0

Hz, CH_2), 3.26 (1H, pent, J 8.5 Hz, CH), 3.44 (1H, d, J

15.5 Hz, CH_2), 3.75 (2H, d, J 15.5 Hz, CH_2), 3.76 (1H,

25 d, J 16.5 Hz, CH_2), 3.90 (1H, d, J 13.5 Hz, CH_2), 3.96

(1H, d, J 13.5 Hz, CH_2), 4.15 (1H, d, J 16.5 Hz, CH_2),

6.84 (1H, d, J 7.5 Hz, ArH), 7.05 (1H, dt, J 1.0, 7.5 Hz, ArH), 7.11-7.36 (6H, m, ArH), 7.64 (1H, d, J 7.5 Hz, ArH).

5   **Example 20**

N-Benzyl-N-[3-(5-cyclobutyl-4,5-dihydroxy-1,3,4,5-tetrahydrobenzo[c]azepin-2-yl)propyl]-2,2,2-trifluoroacetamide **20**:

10   At room temperature the nosylate **15** (120 mg, 0.287 mmol, 1 eq.) and K_2CO_3 (129 mg, 0.933 mmol, 3.25 eq.) in DMF (5 cm^3) was treated with phenylmercaptan (44 □L, 0.428 mmol, 1.49 eq.). Stirring was continued for 24 h before the reaction mixture was exhaustively extracted

15   with EtOAc (5 x 25 cm^3) and H_2O (25 cm^3). The combined organic extracts were dried over $MgSO_4$, filtration followed by solvent removal *in vacuo* afforded the crude diol **16**. A mixture of the crude diol **16** (*ca.* 0.287 mmol, 1 eq.) the aldehyde **3** (223 mg, 0.861 mmol, 3

20   eq.), $NaBH_3CN$ (18 mg, 0.286 mmol, 0.99 eq.) in MeOH (5 cm^3) with a drop of conc. HCl were stirred at room temperature for 15 h. The reaction mixture was extracted with Et_2O (5 x 25 cm^3) and 1 M NaOH (25 cm^3), dried over $MgSO_4$. Filtration followed by solvent

25   removal under reduced pressure afforded the crude adduct which was purified by column chromatography (Pet:EtOAc; 3:1, 1% TEA → Pet:EtOAc; 1:1, 1% TEA) gave the *title compound* **20** (104 mg, 76%). R_f = 0.1 (Pet:EtOAc; 3:1, 1% TEA); 0.3 (Pet:EtOAc; 1:1, 1%

TEA); m/z (CI) 477 (MH$^+$, 100%); found (EI) 476.2287,

$C_{26}H_{31}N_2O_3F_3$ requires 476.2290 (-0.8 ppm); δ_H (300 MHz,

$CDCl_3$) 1.28-1.45 (1H, m, CH_2), 1.63-1.91 (3H, m, CH_2),

2.14-2.36 (2H, m, CH_2), 2.45-2.59 (2H, m, CH_2), 2.61-

2.72 (2H, m, CH_2), 2.75-2.96 (2H, m, CH_AH_B, CH), 2.98-

3.05 (1H, m, CH_AH_B), 3.22-3.42 (2H, m, CH_2), 3.50-3.61

(1H, m, $CH_{A'}H_{B'}$), 3.62-3.75 (1H, m, CH), 3.75-3.82 (1H,

m, $CH_{A'}H_{B'}$), 4.52$^\wedge$ (1H, d, J 14.5 Hz, CH_2), 4.56* (1H,

d, J 15.5 Hz, CH_2), 4.69* (1H, d, J 15.5 Hz, CH_2),

4.82$^\wedge$ (1H, d, J 14.5 Hz, CH_2), 7.05-7.18 (2H, m, ArH),

7.19-7.25 (1H, m, ArH), 7.25-7.45 (5H, m, ArH), 7.80-

7.88 (1H, m, ArH). ^{1}H-NMR complicated due to rotameric

structures [60*:40$^\wedge$].

Example 21

N-Benzyl-N-[3-(5-cyclobutyl-5-hydroxy-4-oxo-1,3,4,5-
tetrahydrobenzo[c]azepin-2-yl)propyl]-2,2,2-
trifluoroacetamide **21**:

A solution of $(COCl)_2$ (98 μL, 1.12 mmol, 3 eq.) in DCM

(3 cm^3) was treated at -78°C with DMSO (133 μL, 1.87

mmol, 5 eq.). Stirring was continued for 10 min.

before a solution of **20** (179 mg, 0.376 mmol, 1 eq.) in

DCM (3 cm^3) was added in a dropwise fashion. This

flask was washed with DCM (2 cm^3) and this was also

added. The reaction mixture was stirred for 1 h during

which time the temperature reached 0°C. TEA (0.31 cm^3,

48

2.22 mmol, 6 eq.) was added to the reaction mixture and stirring was continued for 0.5 h. H_2O (25 cm^3) and Et_2O (25 cm^3) were added and the resultant aqueous layer was further extracted with Et_2O (4 x 25 cm^3) and

5   the combined organic extracts were dried over $MgSO_4$. Filtration followed by solvent removal and purification by flash column chromatography (Pet:EtOAc; 5:1, 1% TEA) afforded **21** (120 mg, 67%) as a yellow oil. R_f = 0.3 (Pet:EtOAc; 5:1, 1% TEA); υ_{max} (neat/cm^{-1}) 3466, 3065,

10   2942, 2861, 1691, 1452, 1376, 1202, 1144; m/z (CI) 475 (MH^+, 5%), 261 (40%), 221 (80%), 108 (100%), 91 (90%); found 475.2205, $C_{26}H_{29}N_2O_3F_3 \cdot H$ requires 475.2208 (-0.6 ppm); δ_H (200 MHz, $CDCl_3$) 1.49-1.98 (8H, m, CH_2), 2.18-2.40 (2H, m, CH_2), 3.28-3.60 (4H, m, CH_2, CH_AH_B, CH),

15   3.74-3.90 (2H, m, CH_AH_B, $CH_{A'}H_{B'}$), 4.15-4.31 (1H, m, $CH_{A'}H_{B'}$), 4.55-4.73 (2H, m, CH_2), 6.95-7.01 (1H, m, ArH), 7.10-7.45 (7H, m, ArH), 7.71-7.83 (1H, m, ArH). ^1H-NMR complicated due to rotameric structures.

20   **Example 22**

2-[3-(Benzylamino)propyl]-5-cyclobutyl-5-hydroxy-1,2,3,5-tetrahydrobenzo[c]azepin-4-one **22**:
At room temperature a solution of **21** (80 mg, 0.169

25   mmol, 1 eq.) in MeOH (10 cm^3) was treated with a solution of K_2CO_3 (117 mg, 0.847 mmol, 5 eq.) in H_2O (0.6 cm^3). Stirring was maintained for 24 h. Solvent removal *in vacuo* followed by purification by flash

49

column chromatography (Pet:EtOAc; 1:2, 1% TEA) gave the
title compound **22** (50 mg, 80%) as a yellow oil. R_f =
0.2 (Pet:EtOAc; 1:2); m/z (CI) 379 (MH$^+$, 50%), 284
(50%), 267 (55%), 108 (100%); found 379.2381,

$C_{24}H_{30}N_2O_2 \cdot H$ requires 379.2385 (-1.1 ppm); δ_H (300 MHz,
CDCl$_3$) 1.41-1.88 (7H, m, CH$_2$), 2.13-2.28 (1H, m, CH$_2$),
2.38 (2H, dt, J 3.5, 7.0 Hz, CH$_2$), 2.59 (2H, t, J 7.0
Hz, CH$_2$), 3.39-3.51 (1H, m, CH), 3.45 (1H, d, J 15.75
Hz, CH$_2$), 3.68 (1H, d, J 15.75 Hz, CH$_2$), 3.69 (2H, s,
CH$_2$), 3.85 (1H, d, J 16.25 Hz, CH$_2$), 4.14 (1H, d, J
16.25 Hz, CH$_2$), 6.97 (1H, d, J 7.5 Hz, ArH), 7.11 (1H,
dt, J 1.5, 7.5 Hz, ArH), 7.14-7.26 (6H, m, ArH), 7.67
(1H, d, J 7.5 Hz, ArH); δ_C (75 MHz, CDCl$_3$) 17.2, 21.6,
21.7, 27.4, 30.3, 41.7, 47.1, 52.5, 60.1, 64.1, 84.0,
127.0, 127.3, 127.4, 128.0, 128.4, 129.6, 134.5, 138.4,
207.7.

Pharmacology

Functional assays of M1, M2 and M3 receptor activity

Initial evaluation of test compounds is by assay
of functional tissue responses. This has the advantage
that it readily discriminates between agonist partial
agonist and antagonist activity

M1 - Vas deferens preparations

Male New Zealand white rabbits (1.47 - 3.4 kg) are
killed by a blow to the back of the head and vasa
deferentia removed, dissected free of connective tissue
and divided into prostatic and epididymal portions.
Each segment is mounted on a tissue holder and passed
through two ring electrodes (5mm apart). They are
immersed in a modified low Ca2+ Krebs solution at

32?0.51C and gassed with 5% CO2 in oxygen. Yohimibine
(1.0mM) is present throughout to block prejunctional
a2-adrenoceptros. The upper end of the tissue is
attached by cotton thread to an isometric transducer

5   (MLT020, ADInstruments). Tissues are left to
equilibrate for at least 45 min at passive force of
0.75-1g. Field stimulation is then applied by repeated
application of single pulses (30V, 0.05Hz, 0.5ms).
Isometric tension is recorded by computer at a sampling

10 rate of 100HZ, using Powerlab/200 (ADInstruments)
software and MacLab bridge amplifiers.

M2 - Guinea-pig atria

Guinea-pigs are killed by a blow to the back of
the head and left atrium removed. The atrium is

15 secured to a pari of stainless steel electrodes by
means of a cotton thread and immersed in the organ bath
containing gassed Krebs solution with normal Ca^{2+} at
32±0.5°C. Atria are placed at 2Hz with square-wave
pulses of 0.5ms pulse width. Isometric contractions

20 are recorded by computer or polygraph.

M3 - Guinea-pig ileum

Sections (2 cm) are cut from the ileum of the
killed guinea-pigs, 10cm from the ileo-caecal junction.
One end is attached to a tissue holder/aerator and the

25 other end via a cotton thread to an isometric
transducer. The tissue is immersed in gassed normal
Ca^{2+} Krebs solution at 32±0.5°C. A resting tension of
0.5g is applied and isometric contractions measured by
computer or polygraph.

30 **Agonist concentration-response curves**

Following at least 30 min equilibration to allow
twitches or tension to stabilize, cumulative
concentration-response curves for the muscarinic

agonists are constructed. The concentration is increased in half logarithmic increments after the contraction in the presence of each concentration has plateaued Steady-state contractions at each

5   concentration are measured and the inhibition expressed as a percentage of the baseline twitch height in atria and vas deferens or as the maxi contraction in the ileum. EC50 values for the muscarinic agonists are determined from individual curves as the molar

10   concentration required for 50% inhibition of twitch height or the 50% of maximum contraction (ileum). Geometric mean EC50 values and their 95% confidence limits are calculated.

Effects of muscarinic antagonists

15   A concentration-response curve to the test agonist is established in the absence of antagonist and after achieving the maximum effect, the agonist washed from the bath to restore twitch contractions. Three further concentration-response curves are then obtained in the

20   same manner at approximately 30 min intervals, with the antagonist (Standards - pirenzepine M1, darifenacin M3, methoctramine M2) being introduced to the bath 15 min before each of these subsequent curves.

Calculation of antagonist pA$_2$ values

25   Concentration-response curves in the absence and presence of antagonist are measured as described for the agonist studies. The shifts in the concentration-response curves in the presence of antagonist compared with the absence of antagonist are expressed as the

30   dose-ratios (DR) of the EC50 values. pA$_2$ values are then determined from Schild analysis of plots of the mean corrected -log(DR-1) against log molar concentration of antagonist. The slopes of the Schild

plots are determined by linear regression and the pA_2
values determined from the intercept on the
concentration axis (when log(DR-1) is zero). pA_2 values
are also determined from individual concentrations of

5   antagonist by applying the equations: pA_2 = log(DR-1) =
log[B], wherein B is the molar concentration of
antagonist.

Standard Drugs

     Carbamoylcholine chloride (carbachol),

10   methacholine, methactramine, pirenzepine
dihydrochloride, yohimbine hydrochloride (Sigma, Poole,
Dorset, UK), darifenacin (Pfizer, Sandwich, Kent), McN-
A343 [4-(4-chlorophenylcarbamoyloxy)-2-butynyl-
trimethylammonium iodide] and oxotremorine

15   sesquifurnarate (RBI, St. Albans, UK). AR drugs are
dissolved in distilled water initially and dilutions
made in Krebs solution.

Reference data

     The reproducibility of the concentration-response

20   curves and stability of each tissue over several hours
was established. EC50 values were obtained for a range
of reference agonists in each tissue - methacholine,
oxotremorine, McN-A-343 to permit comparisons with the
novel agents of the invention. pA_2 values for reference

25   antagonists were obtained in relevant tissues -
pirenzepine (M1 selective), darifenacin (M3 selective).
It is as a result possible to establish the functional
characterization of the three receptor types to enable
determination of the potency (EC50 of agonist, pA_2 or

30   affinity of antagonist molecules) and selectively of
the novel agents of the invention.

The compounds of Examples 19 and 22 were tested as described above and the results obtained were as follows:

Compound	M3 (ileum)	M3 (Atria)	Log_{10} selectivity
Compound 22 (Example 22)	6.7±0.4 (4 pts)	5.2±0.3 (4 pts)	1.5 ± 0.5
Compound 19 (Example 19)	6.5±0.4 (3 pts)	4.9±0.6 (4 pts)	1.6 ± 0.7

5

-54-

CLAIMS:

1.   A compound having the formula:

wherein:

R_{1a}, R_{1b} and R_{1c} are independently fluorine or hydrogen;

R_2 is C_1 to C_{12} alkyl, said alkyl being straight or branched chain, saturated or unsaturated, mono-substituted or unsubstituted, said substituents being selected from piperidine, pyrrolidine, morpholine, thiomorpholine, tetrahydrofuran, thiophen, furan and cycloalkyl of 3 to 7 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms (preferably 4 to 9 carbon atoms) having a C_1 to C_6 alkyl substituent; a polycycloalkyl of 2 to 3 rings having 7 to 12 carbons; and phenyl or phenyl singly or multiply substituted (preferably singly or doubly) with halogen, hydroxy, C_1 to C_6 alkoxy, C_1 to C_6 alkyl, nitro, methylene dioxy or trifluoromethyl; and

R_3 is a moiety selected from:

I   II

or a pyrrolidin-3-yl moiety of the formula

-55-

$$
\begin{array}{c}
R_6 \\
\diagup \\
\diagdown \diagup{-R_4} \\
N \\
\mid \\
R_5
\end{array}
$$

III

where R_6 is hydroxy or hydrogen;

where one of R_4 and R_5 is hydrogen or lower C1-3 alkyl and the other is selected from:

(a)   hydrogen,

(b)   phenyl,

(c)   phenyl singly or multiply substituted with halogen, hydroxy, C_1 to C_6 alkoxy, C_1 to C_6 alkyl, nitro, methylene dioxy or trifluoromethyl,

(d) C_1 to C_6 alkyl which may be branched chain or straight, saturated, unsaturated, or cyclic and may be optionally substituted with hydroxy, thienyl, pyrrolyl, pyridyl, furanyl, lower alkoxy or acetoxyalkyl wherein the alkyl group has 1 to 3 carbons, phenyl, phenyl singly or multiply substituted (preferably singly or doubly) with halogen, hydroxy, C_1 to C_{10} alkoxy, C_1 to C_{10} alkyl, nitro, methylene dioxy (optionaly mono or di-alkyl substituted where the alkyl substituent has from 1 to 10 carbon atoms) or trifluoromethyl;

or a pharmaceutically acceptable salt thereof

2.   A compound according to claim 1, wherein R_2 is cycloalkyl of 3 to 6 carbon atoms.

3.   A compound according to claim 2, wherein R_2 is cyclobutyl.

4.   A compound according to any preceding claim, wherein R_4 is hydrogen and R_5 is selected from amongst the groups (a)-(d) as defined in claim 1.

5.   A compound according to any one of claims 1 to 3, wherein one of R_4 and R_5 is hydrogen (or methyl in the case of R_5) and the other is selected from hydrogen,

C_1 to C_6 alkyl which may be branched chain or straight, saturated, unsaturated, or cyclic and may be optionally substituted with hydroxy, thienyl, pyrrolyl, pyridyl, furanyl, phenyl, phenyl singly or multiply substituted (preferably singly or doubly) with halogen, hydroxy, C_1 to C_{10} alkoxy, C_1 to C_{10} alkyl or nitro.

6.   A compound according to claim 5, wherein R_4 is hydrogen and R_5 is C_1 to C_6 alkyl substituted by phenyl or phenyl which is singly or multiply substituted with halogen, hydroxy, C_1 to C_{10} alkoxy, C_1 to C_{10} alkyl or nitro.

7.   A compound according to claim 6, wherein R_5 is benzyl, substituted benzyl or cinnamyl.

8.   A compound according to claim 7, wherein R_5 is substituted benzyl in which the substituent(s) on the benzyl are independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl.

9.   A compound according to any preceding claim, wherein R_6 is hydrogen.

10.   A compound according to claim 1, wherein R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is

where R_4 is hydrogen and R_5 is selected from C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, and R_6 is hydrogen or hydroxy.

11.   A compound according to claim 10, wherein R_2 is cyclobutyl and R_5 is substituted benzyl in which the substituent(s) on the benzyl are independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl.

12.   A compound according to claim 10 or 11, wherein R_6 is hydrogen.

13.   A compound according to claim 1, wherein R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is


where R_4 is hydrogen and R_5 is selected from C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl, and R_6 is hydroxy or hydrogen.

14.   A compound according to claim 13, wherein R_2 is cyclobutyl and R_5 is substituted benzyl in which the substituent(s) on the benzyl are independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl.

15.   A compound according to claim 13 or 14, wherein R_6 is hydrogen.

16.   A compound according to claim 15, wherein R_{1a}, R_{1b} and R_{1c} are independently hydrogen or fluorine, R_2 is cycloalkyl of 3 to 6 carbon atoms or phenyl, R_3 is a moiety having the following structure:

where R_4 is hydrogen and R_5 is selected from C_1 to C_6 alkyl, benzyl, substituted benzyl or cinnamyl.

17.   A compound according to claim 16, wherein R_2 is cyclobutyl and R_5 is substituted benzyl in which the substituent(s) on the benzyl are independently halo, C_1 to C_{10} alkoxy or C_1 to C_{10} alkyl.

-58-

18. A compound according to any preceding claim, wherein R_{1a}, R_{1b} and R_{1c} are each hydrogen.

19. A compound according to claim 1, which is 2-[2-(benzylamino)ethyl]-5-cyclobutyl-5-hydroxy-1,3,4,5-tetrahydrobenzo[c]azepin-4-one, or a pharmaceuticaly acceptable salt thereof.

20. A compound according to claim 1, which is 2-[3-(Benzylamino)propyl]-5-cyclobutyl-5-hydroxy-1,2,3,5-tetrahydrobenzo[c]azepin-4-one, or a pharmaceuticaly acceptable salt thereof.

21. A pharmaceutical composition comprising a compound according to any preceding claim and a pharmaceutically acceptable carrier or diluent.

22. A compound as claimed in any one of claims 1 to 20, for use as a muscarinic antagonist with M_3 selectivity.

23. A compound for use as claimed in claim 22, as a bronchodilator, an antispasmodic agent, an antisecretory agent, an agent having antiulcer activity or a agent for the treatment of patients suffering from neurogenic bladder disorders.

24. A process for synthesising a compound according to claim 1, which includes the step of subjecting a compound of the formula (X):

X

in which R1a, R1b, R1c and R2 are as defined in claim 1 and R3 is as defined in claim 1 suitably protected to oxidation conditions sufficient to oxidise the alcohol group at the 4-position of the benzo[c]azepine core to a ketone group.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7   C07D223/16   A61K31/55   A61P11/08   A61P13/10   A61P1/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   C07D   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ, EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 02, 29 February 1996 (1996-02-29) & JP 07 258250 A (YAMANOUCHI PHARMACEUT CO LTD), 9 October 1995 (1995-10-09) abstract ─────	1-24

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
30 August 2001	10/09/2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Schmid, J-C

Form PCT/ISA/210 (second sheet) (July 1992)

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 07258250 A	09-10-1995	NONE	